Guanidines

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Natural sciences, Chemistry, Branches of biology, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, BioCryst Pharmaceuticals, Peramivir, Neuraminidase, Viral neuraminidase, Enzyme

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

Health Logic Interactive Announces Proof-of-Concept Test Results and Advancement of its Lab-on-Chip Technology

Retrieved on: 
Monday, June 14, 2021
Mental processes, Logic, Academic disciplines, Proof theory, Philosophical logic, Philosophy of logic, Creatinine, Guanidines, Metabolism, Formal proof, Mathematical logic

CALGARY, AB, June 14, 2021 /PRNewswire/ -Health Logic Interactive Inc. ("Health Logic" or the "Company") (TSXV: CHIP.H)(OTCPK: CHYPF) is pleased to report positive preliminary proof-of-concept test results of its first urine creatinine chip prototype (uC-Chip beta version), which successfully validated the clinically relevant detection range.

Key Points: 
  • CALGARY, AB, June 14, 2021 /PRNewswire/ -Health Logic Interactive Inc. ("Health Logic" or the "Company") (TSXV: CHIP.H)(OTCPK: CHYPF) is pleased to report positive preliminary proof-of-concept test results of its first urine creatinine chip prototype (uC-Chip beta version), which successfully validated the clinically relevant detection range.
  • Health Logic is pleased to announce these developments as the Company prepares for its pre-submission meeting with the United States Food and Drug Administration.
  • Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com .
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/health-logic-interactive-announc...
    SOURCE Health Logic Interactive Inc.

Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease

Retrieved on: 
Thursday, June 10, 2021
Diabetes, Other Health, Pharmaceutical, Women, Seniors, Hospitals, Fitness & Nutrition, MEN, Clinical trials, Science, Biotechnology, Consumer, Other Science, Health, Research, Drugs, Clinical medicine, Health, Biguanides, Guanidines, Metformin, Anti-diabetic drugs, Diabetes, Type 2 diabetes, Insulin, Dapagliflozin, Pioglitazone/metformin

Anji Pharma (Anji) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.

Key Points: 
  • Anji Pharma (Anji) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.
  • Without metformin, T2D patients with advanced CKD often require high doses of insulin to achieve glucose control, which can increase the risk of severe hypoglycemia.
  • Based on recent evidence that metformins glucose-lowering effects are largely attributed to direct action at the gut wall, Anji is developing a gut-targeted metformin for use in T2D patients with kidney disease.
  • Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients as efficiently as possible.

Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19

Retrieved on: 
Thursday, June 3, 2021
Health sciences, Health, Chemical compounds, Clinical research, Pharmaceutical industry, Brilacidin, Guanidines, Pyrimidines, Pyrrolidines, Clinical trial, COVID-19, Casirivimab/imdevimab

WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).

Key Points: 
  • WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).
  • Innovation Pharmaceuticals is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
  • Complete trial enrollment comprised 120 dosed patients recruited across multiple sites.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

Retrieved on: 
Thursday, May 27, 2021
Health sciences, Health, Chemical compounds, Antibiotics, Brilacidin, Guanidines, Pyrimidines, Pyrrolidines, Clinical research, Clinical trial, COVID-19

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.

Key Points: 
  • WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.
  • Innovation Pharma is developing Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients under U.S. FDA Fast Track designation (see NCT04784897 ).
  • The Company intends to provide an update to shareholders upon the final patients entering the trial.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.

AACC Releases Guidance on Improving Care for Acute Kidney Injury With Clinical Laboratory Tests

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Renal physiology, Creatinine, Guanidines, Metabolism, Nephrology, Kidney diseases

It is therefore essential that clinical laboratory professionals and clinicians know what the right tools are for diagnosing AKI.

Key Points: 
  • It is therefore essential that clinical laboratory professionals and clinicians know what the right tools are for diagnosing AKI.
  • However, current approaches to detecting this condition differ widely throughout the medical community due to factors such as inconsistent integration of new findings on AKI into clinical practice.
  • To remedy this, AACC\'s guidance proposes using new diagnostic thresholds, known as the 20/20 AACC AKI criteria, to determine whether a patient has AKI with creatinine testing.
  • Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, Neuraminidase, BioCryst Pharmaceuticals, XC2, Viral neuraminidase

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Report First Quarter 2021 Financial Results on May 6

Retrieved on: 
Thursday, April 22, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, XC2, Conference call

b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.\nThe live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434.
  • A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com .
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Branches of biology, Chemistry, Neuraminidase inhibitors, Natural sciences, Carbohydrate chemistry, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, Viral neuraminidase, Enzyme

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the companys website at www.biocryst.com .

Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, April 5, 2021
Chemical compounds, Food and Drug Administration, Antibiotics, Brilacidin, Guanidines, Pyrimidines, Pyrrolidines, Health, Life sciences, Fast track

Upon reaching 25 percent enrollment (30 subjects), recruitment was paused and a pre-specified unblinded safety data review and evaluation was conducted by the DMC.

Key Points: 
  • Upon reaching 25 percent enrollment (30 subjects), recruitment was paused and a pre-specified unblinded safety data review and evaluation was conducted by the DMC.
  • Efficacy data was not reviewed by the DMC and remains blinded.
  • Trial data for Veklury could serve as a benchmark in evaluating Brilacidin outcomes.
  • Innovation Pharma is developing Brilacidin, a defensin-mimetic, under Fast Track designation from the U.S. Food and Drug Administration (FDA).